Translations:Losartan/21/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 22:47, 14 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Losartan)
Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing losartan by [[Sandoz]], [[Torrent Pharmaceuticals]], [[Hetero Drugs|Hetero Labs]], Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, [[Teva Pharmaceutical Industries|Teva Pharmaceuticals]], [[Vivimed Labs|Vivimed Life Sciences]], and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens [[N-nitrosodiethylamine]], N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the [[Active ingredient|active pharmaceutical ingredient]] (API).

Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing losartan by Sandoz, Torrent Pharmaceuticals, Hetero Labs, Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, Teva Pharmaceuticals, Vivimed Life Sciences, and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens N-nitrosodiethylamine, N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the active pharmaceutical ingredient (API).

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Losartan/21/en&oldid=128816"